Literature DB >> 22772554

Mining the mechanisms of an HIV vaccine.

Stanley A Plotkin1, Harriet L Robinson, Miles P Davenport.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22772554     DOI： 10.1038/nm.2858

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Mark B Feinberg; Robert C Gallo; Beatrice Hahn; James A Hoxie; Eric Hunter; Bette Korber; Alan Landay; Michael M Lederman; Judy Lieberman; Joseph M McCune; John P Moore; Neal Nathanson; Louis Picker; Douglas Richman; Charles Rinaldo; Mario Stevenson; David I Watkins; Steven M Wolinsky; Jerome A Zack
Journal:  Science       Date:  2004-01-16       Impact factor: 47.728

2.  HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.

Authors:  Nicole A Doria-Rose; Mark K Louder; Zhongjia Yang; Sijy O'Dell; Martha Nason; Stephen D Schmidt; Krisha McKee; Michael S Seaman; Robert T Bailer; John R Mascola
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

3.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

Review 4.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

5.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

6.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

7.  Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Authors:  Peter B Gilbert; Michael L Peterson; Dean Follmann; Michael G Hudgens; Donald P Francis; Marc Gurwith; William L Heyward; David V Jobes; Vladimir Popovic; Steven G Self; Faruk Sinangil; Donald Burke; Phillip W Berman
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

8.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

9.  Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.

Authors:  Scott G Hansen; Julia C Ford; Matthew S Lewis; Abigail B Ventura; Colette M Hughes; Lia Coyne-Johnson; Nathan Whizin; Kelli Oswald; Rebecca Shoemaker; Tonya Swanson; Alfred W Legasse; Maria J Chiuchiolo; Christopher L Parks; Michael K Axthelm; Jay A Nelson; Michael A Jarvis; Michael Piatak; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2011-05-11       Impact factor: 49.962

Review 10.  The cell biology of receptor-mediated virus entry.

Authors:  Joe Grove; Mark Marsh
Journal:  J Cell Biol       Date:  2011-11-28       Impact factor: 10.539
  10 in total
  2 in total

1.  CD4 mimetics sensitize HIV-1-infected cells to ADCC.

Authors:  Jonathan Richard; Maxime Veillette; Nathalie Brassard; Shilpa S Iyer; Michel Roger; Loïc Martin; Marzena Pazgier; Arne Schön; Ernesto Freire; Jean-Pierre Routy; Amos B Smith; Jongwoo Park; David M Jones; Joel R Courter; Bruno N Melillo; Daniel E Kaufmann; Beatrice H Hahn; Sallie R Permar; Barton F Haynes; Navid Madani; Joseph G Sodroski; Andrés Finzi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

2.  CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies.

Authors:  Navid Madani; Amy M Princiotto; Arne Schön; Judith LaLonde; Yu Feng; Ernesto Freire; Jongwoo Park; Joel R Courter; David M Jones; James Robinson; Hua-Xin Liao; M Anthony Moody; Sallie Permar; Barton Haynes; Amos B Smith; Richard Wyatt; Joseph Sodroski
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.